FDA/CDC
Conference Coverage
ACIP votes unanimously in favor of immunization schedule update and redesign
Conference Coverage
ACIP supports hepatitis A vaccine for homeless individuals
FDA/CDC
Rivaroxaban gains indication for prevention of major cardiovascular events in CAD/PAD
Rivaroxaban (Xarelto) is the first direct oral anticoagulant to gain an indication for prevention of cardiovascular events.
FDA/CDC
FDA expands approval of 9-valent HPV vaccine
Gardasil-9 is now approved for men and women aged 27-45 years.
FDA/CDC
Emgality approved for migraine prevention in adults
The calcitonin gene–related peptide antagonist was tested in both episodic and chronic migraine.
FDA/CDC
FDA approves Ajovy for migraine prevention
The injection is available in a 225-mg dose monthly or a 675-mg dose every 3 months.
FDA/CDC
FDA alert: Artificial heart driver linked to higher mortality
FDA/CDC
CDC: 2017 worst year yet for drug overdoses
Deaths tied to synthetic opioids climbed faster than any other drug class.
FDA/CDC
FDA approves Orilissa for endometriosis pain
Orilissa (elagolix) is the first FDA-approved oral treatment for moderate to severe endometriosis pain in more than a decade.
FDA/CDC
Fluoroquinolones can cause fatal hypoglycemia, FDA warns